To study the electrophysiological and pharmacological properties of the L-type Ca 2ϩ channel (LTCC) Ca v 1.4␣1 (␣1F) subunit from mouse retina and assess their contributions to the native retinal channel. METHODS. The full-length cDNA of Ca v 1.4␣1 was cloned from murine retina in an RT-PCR approach. Ca v 1.4␣1 was expressed alone or together with the auxiliary ␣2␦1 and ␤2a or ␤3 subunits in HEK293 cells. The electrophysiological and pharmacological characteristics of L-type Ca 2ϩ and Ba 2ϩ inward currents (I Ca and I Ba ) induced by Ca v 1.4␣1 were determined by the whole-cell configuration of the patch-clamp method and compared with currents induced by the cardiac and smooth muscle-type Ca v 1.2␣1 (␣1C) channel. RESULTS. Ca v 1.4␣1-mediated I Ba was observed only when the ␣2␦1 and ␤ subunits were coexpressed. Current densities were approximately two times higher with ␤2a than with ␤3. current. Its intrinsic biophysical properties, in particular its unique inactivation properties, enable Ca v 1.4␣1 to provide a sustained I Ca over a voltage range such as required for tonic glutamate release at the photoreceptor synapse. (Invest Ophthalmol Vis Sci. 2004;45:708 -713)
T he release of neurotransmitters from nerve terminals is initiated by Ca 2ϩ -influx through presynaptic voltage-dependent Ca 2ϩ channels. Recent studies indicate that L-type Ca 2ϩ channel (LTCCs) play a key role in the control of tonic glutamate release from retinal photoreceptors and bipolar cells. [1] [2] [3] LTCCs recorded from photoreceptors 4 -7 and bipolar cells 8 -10 possess biophysical and pharmacological properties that set these channels apart from other LTCCs, such as cardiac and smooth muscle LTCCs. These unique properties include fast activation and very slow inactivation kinetics, as well as relatively low sensitivity to DHPs. LTCCs are not restricted to the synaptic layers of the retina. They have also been described in the cell soma of photoreceptors and in somatodendritic localization in bipolar and ganglion cells. 10 -12 These LTCCs are thought to supply the Ca 2ϩ entry essential in more general cellular functions, such as Ca 2ϩ -mediated signal transduction or the regulation of gene transcription. 13 LTCCs are multisubunit proteins consisting of the principal ␣ 1 and the auxiliary ␤ and ␣2␦ 14, 15 subunits. Some LTCCs, such as the skeletal muscle Ca 2ϩ channel contain an additional ␥ subunit.
14 Whereas ␣ 1 subunits determine the principal biophysical and pharmacological properties of the channel, ␤ subunits modulate cell surface expression, voltage dependence, and opening kinetics. So far, the functional role of the ␣2␦ and the ␥ subunit have been less well investigated.
Three different LTCC ␣ 1 subunits have been detected in the neuroretina, Ca v 1.2␣1 (␣1C), Ca v 1.3␣1 (␣1D), and Ca v 1.4␣1 (␣1F). 12 In contrast to Ca v 1.2␣1 and Ca v 1.3␣1 which are expressed in a variety of tissues, Ca v 1.4␣1 seems to be specifically expressed in the retina. 16, 17 Recently, mutations in the gene encoding Ca v 1.4␣1 (CACNA1F) have been identified in patients who have incomplete X-linked congenital stationary night blindness 16 -19 (CSNB2). The key symptoms of this disease are impaired night vision and decreased visual acuity. The electrophysiological hallmark is the Schubert and Bornschein type electroretinogram, in which the amplitude of the scotopic b-wave is smaller than that of the normal sized a-wave. This finding suggests that the pathologic correlate of the disease is localized most likely at the photoreceptor-to-bipolar synapse. 20 Although the genetic studies indicate that the functional loss of Ca v 1.4␣1 causes CSNB2, the molecular mechanism by which mutations in this channel lead to disease is not understood. To address this important question in a physiological context, mouse models of this channelopathy are needed. To this end, we set out in this study to clone and functionally express the complete cDNA of Ca v 1.4␣1 from mouse retina. The biophysical and pharmacological properties of Ca v 1.4␣1-mediated calcium currents concurred well with those of calcium currents from photoreceptors and bipolar cells.
MATERIALS AND METHODS

Cloning of Murine Ca v 1.4␣1
Total RNA was purified from retinas of C57Bl6 mice using the phenolguanidine-isothiocyanate-chloroform extraction protocol (PeqGOLD Trifast; PeqLab, Erlangen, Germany). All animals were used in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. First-strand cDNA synthesis was performed with 5 g total RNA, using oligo d(T) primer and reverse transcriptase (Superscript II; Invitrogen, Karlsruhe, Germany). To obtain the complete coding region of Ca v 1.4␣1, three overlapping PCR fragments were amplified from the cDNA using the expand long template PCR system (Roche Diagnostics, Mannheim, Germany). The primers were designed according to the murine Ca v 1.4␣1 sequence AF192497 (Table 1). The PCR fragments were subcloned into pUC18 or pcDNA3 (Invitrogen, Karlsruhe, Germany) and several clones for each fragment were sequenced on both strands using the a chain terminator cycle sequencing kit (BigDye Terminator; Applied Biosystems, Foster City, CA Currents were recorded at room temperature 2 to 4 days after transfection, using the whole-cell patch-clamp technique. Data were acquired at 10 kHz with an amplifier (Axopatch 200B with pClamp 8; Axon Instruments, Foster City, CA). Voltage-clamp data were stored on the computer hard disc and analyzed off-line (Clampfit 8; Axon Instruments, and Origin 6.1; OriginLab Co., Northampton, MA).
Patch pipettes were pulled from borosilicate glass and when filled with pipette solution, their input resistance was between 1.2 and 2.0 M⍀. Typical cell sizes were between 15 and 60 pF. Access resistances were between 3.0 and 4.0 M⍀ and were compensated up to 70%. The holding potential was Ϫ80 mV, unless stated otherwise.
The peak I-V relationship was measured by applying 150-ms voltage pulses to potentials between Ϫ80 and ϩ70 mV in 10-mV increments from a holding potential of Ϫ80 mV at 0.2 Hz. To obtain current densities, the current amplitude at V max was normalized to cell membrane capacitance (C m ). From I-V curves the activation threshold was determined as the test potential at which 5% of the maximum current was activated.
For determination of half-maximum activation voltage (V 0.5,act ) the chord conductance (G) was calculated from the current voltage curves by dividing the peak current amplitude by its driving force at that respective potential G ϭ I/(V Ϫ V rev ), where V rev is the extrapolated reversal potential, V is the membrane potential, and I is the peak current. The chord conductance was then fitted with a Boltzmann equation G ϭ G max /(1 ϩ e (V0.5,actϪVm)/kact ), where G max is the maximum conductance, V 0.5,act is the half-maximum activation voltage, V m is the test potential, and k act is the slope factor of the activation curve.
For determination of half-maximum inactivation voltage (V 0.5,inact ) steady state inactivation curves were measured from a holding potential of Ϫ80 mV, by using a series of conditioning prepulses of different length to various voltages between Ϫ100 mV and ϩ50 mV. For Ca v 1.2␣1, the duration of the conditioning prepulse was 5 seconds, for Ca v 1.4␣1 pulses of 5, 10, 20, and 30 seconds were applied to achieve steady state. The conditioning pulse was followed by a 20-ms return to the holding potential and a 300-ms test pulse to V max at 0.1 Hz or 0.05 Hz. Tail currents immediately after the final step to V max were normalized to maximum current amplitude and plotted as a function of the preceding membrane potential. The data points were fitted with the Boltzmann function:
) where V m is the test potential, V 0.5,inact is the half-maximum voltage for steady state inactivation, and k is the slope factor of the curve.
The time course of Ca v 1.2␣1 current activation was fitted by the monoexponential function: I t ϭ A 0 ⅐ e (Ϫt/) ϩ C, where I t is the current at time t after a voltage pulse to V max , A 0 is the steady state current amplitude with the respective time constant of activation, , and C is the remaining steady state current. Ca v 1.4␣1 current activation was fitted by the biexponential function:
(Ϫt/slow) ϩ C, where slow and fast represent slow and fast time constants of activation, respectively.
To characterize the pharmacological properties of Ca v 1.4␣1, we tested LTCC antagonists and the agonistic DHP BayK 8644. Drugs were applied by a local solution exchanger and reached the cell membrane within less than 100 ms. The effects of the antagonists were tested with 40-ms voltage-clamp steps to 0 mV or ϩ10 mV from HPs of Ϫ80 mV or Ϫ50 mV. Pulse frequency was 0.2 Hz. For each test configuration, drug effects were measured after steady state block was attained within 2 to 3 minutes after drug application. For each antagonist the ratio I drug /I control was calculated from the peak current-voltage relations. The concentration-inhibition curve derived from responses at four to five different concentrations was obtained by fitting I drug /I control to the Hill equation
nH , where C is the drug concentration, n H is the Hill coefficient, and IC 50 is the drug concentration needed for half-maximum block.
Stock solutions of drugs were prepared in H 2 O or ethanol (isradipine) and stored at ϩ4°C in the dark. For electrophysiological measurements, stock solutions were freshly diluted in bath solution. Racemic verapamil HCl, D-cis-diltiazem, and S-(-)Bay K8644 were obtained from Sigma-Aldrich Corp. (St. Louis, MO), L-cis-diltiazem was purchased from Biomol Research Laboratories Inc. (Plymouth Meeting, PA), and racemic isradipine was a gift from Novartis Pharma AG (Basel, Switzerland).
Statistics
All results are expressed as the mean Ϯ SEM; n is the number of experiments. An unpaired t-test was performed for the comparison between two groups. Significance was also tested by ANOVA, if multiple comparisons were made. P Ͻ 0.5 was considered significant. 
RESULTS
Molecular Cloning of Murine Ca v 1.4␣1
To clone murine Ca v 1.4␣1 we designed specific primer pairs based on the previously published sequence of this channel (Table 1 ) 23 and performed RT-PCR with retinal cDNA from mouse strain C57Bl6. The full-length cDNA of Ca v 1.4␣1 was determined to be 6111 bp with an open reading frame encoding a protein of 1984 amino acid residues (GenBank accession number of murine Ca v 1.4␣1: AJ579852; available by ftp at zippy.nimh.nih.gov/ or at http://rsb.info.nih.gov/nih-image; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD). The sequence is nearly identical with the mouse sequence published by Naylor et al. 23 with the notable exception of a strongly diverging sequence stretch in the C terminus (amino acid residues 1768-1807). Inspection of the nucleotide sequences revealed that the profound differences in this stretch arise from frame shifts in the cDNA. The strong homology between the sequence published in this study to that of rat and human Ca v 1.4␣1 16, 17, 20 (see sequence alignment in Supplemental Figure 1 , available online at http:// www.iovs.org/cgi/content/full/45/2/708/DC1) strongly indicates that our sequence version represents the correct one. 
Electrophysiological Properties
pA/pF, n ϭ 7). This finding indicated that Ca v 1.4␣1 was not able to induce the formation of a functional LTCC. In contrast, when Ca v 1.4␣1 was coexpressed with ␣2␦1 and ␤2a subunits, amplitudes of I Ba consistently exceeded those of the endogenous current. In addition, the biophysical properties of the heterologously expressed current were clearly different from those of the endogenous current. Figure  1A shows (Fig. 1B) . The threshold for Ca v 1.4␣1 current activation was Ϫ28 Ϯ 1.2 mV (n ϭ 30), which is 5 mV more negative than Ca v 1.2␣1 current activation (Ϫ23.4 Ϯ 1.9 mV; n ϭ 9). For both ␣ 1 subunits, the peak current occurred at similar V max with 13.8 Ϯ 0.9 mV (n ϭ 30) for Ca v 1.4␣1 and 13.3 Ϯ 1.7 mV (n ϭ 9) for Ca v 1.2␣1 (Fig. 1B) . The peak current densities for Ca v 1.4␣1 was Ϫ9.5 Ϯ 1.1 pA/pF (n ϭ 30) and Ϫ31.4 Ϯ 9.4 pA/pF (n ϭ 9) for Ca v 1.2␣1. To compare the voltage-dependent activation and inactivation of the Ca v 1.4␣1 and Ca v 1.2␣1 currents, normalized conductancevoltage relations and steady state inactivation curves of I Ba were determined and fitted by Bolzmann distributions (Fig.  1C) . The activation curves for both ␣1 subunits were almost identical. The potential of half-maximum I Ba activation (V 0.5,act ) was 1.1 Ϯ 1.0 mV for Ca v 1.4␣1 (n ϭ 28) and Ϫ0.1 Ϯ 1.2 mV for Ca v 1.2␣1 (n ϭ 9). In contrast, at a conditioning pulse duration of 5 seconds, the steady state inactivation curve of Ca v 1.4␣1 was shifted to approximately 20 mV more depolarized potentials with respect to Ca v 1.2␣1. The potential of half-maximum I Ba inactivation (V 0.5,inact ) was 0.64 Ϯ 2.6 mV for the Ca v 1.4␣1 subunit (n ϭ 9) and Ϫ24.3 Ϯ 1.5 mV for the Ca v 1.2␣1 subunit (n ϭ 9).
Voltage-dependent inactivation of Ca v 1.4␣1 was dependent on the length of the conditioning prepulse. Increasing the pulse duration from 5 to 30 seconds increased k inact of the inactivation curve and shifted V 0.5,inact to approximately 25 mV more hyperpolarized voltages (Fig. 2) . There was no significant difference between the inactivation curves for the 20-second and 30-second prepulse duration, indicating that steady state was achieved after 20 seconds.
Ca v 1.4␣1 also formed functional channels with the ␤3 subunit, an auxiliary LTCC subunit that is expressed in the central nervous system (CNS) and in a variety of peripheral tissues. 15 Peak current densities obtained after coexpression of Ca v 1.4␣1 ϩ ␤3 ϩ ␣2␦1 were less than half those recorded in the presence of ␤2a (␤3: Ϫ4.4 Ϯ 0.8 pA/pF, n ϭ 10; ␤2a: Ϫ9.5 Ϯ 1.1 pA/pF, n ϭ 30). However, the biophysical properties of both currents were very similar to each ( Table 2) . As the only exception, the activation threshold was slightly shifted to more hyperpolarized voltages in the presence of ␤3 (␤2a: Ϫ28.0 Ϯ 1.2 mV, n ϭ 30; ␤3: Ϫ37.2 Ϯ 2.4 mV, n ϭ 10). Ca 2ϩ is not only the permeating cation of LTCCs, it is also a key determinant of their inactivation. Figure 3A shows current traces of Ca v 1.4␣1/ ␤2a/␣2␦1 in the presence of 10 mM extracellular Ba 2ϩ or Ca 2ϩ , respectively. Both current traces show identical kinetics, indicating that unlike in the Ca v 1.2␣1 channel, 24 Ca 2ϩ does not accelerate inactivation. However, the current density of I Ca 2␣1 (E; n ϭ 9) and steady state inactivation curves for Ca v 1.4␣1 (f; n ϭ 9) and Ca v 1.2␣1 (Ⅺ; n ϭ 9) were determined. Individual curves were normalized to maximum current amplitude and then averaged. Solid lines: fits of the data to the Boltzmann equation. Inactivation curves were determined using a conditioning prepulse of 5 seconds and a 300-ms test pulse to ϩ10 mV. In addition, 10 mM Ca 2ϩ as the charge carrier shifted the I-V relation to approximately 10 mV more positive voltages without affecting the slope of the activation and inactivation curves (Fig. 3B, Table 2 ).
Pharmacological Characterization of Ca v 1.4␣1
To characterize the pharmacological profile of Ca v 1.4␣1 we quantified the blocking effect of the Ca 2ϩ channel antagonists isradipine, verapamil, L-cis-diltiazem, and D-cis-diltiazem on I Ba . At Ϫ80 mV the DHP antagonist isradipine blocked I Ba elicited by depolarizing pulses to V max given at 0.2 Hz with an apparent IC 50 of 200 Ϯ 50 nM (n ϭ 5-9; Fig. 4A ). At a holding potential of Ϫ80 mV 100 nM isradipine blocked 41.9% Ϯ 0.03% (n ϭ 7) of I Ba . Changing the holding potential to Ϫ50 mV significantly increased the block to 88.3% Ϯ 0.01% (n ϭ 9) of I Ba , indicating a strong voltage-dependence of the observed block (Fig. 4A) . Ca v 1.4␣1 was only weakly sensitive to verapamil. At an HP of Ϫ80 mV 100 M verapamil blocked 69.1% Ϯ 0.13% (n ϭ 5) of I Ba .
We also tested the blocking effect of the two enantiomers of diltiazem under identical conditions. Unexpectedly, the concentration-response relationships were not statistically different from each other (Fig. 4A) . L-cis-Diltiazem blocked I Ba with an IC 50 of 74.8 Ϯ 8.3 M (n ϭ 4 -6), and D-cis-diltiazem blocked I Ba with an IC 50 of 91.6 Ϯ 9.4 M (n ϭ 4 -6) . This observation is very surprising, because the affinity of L-cisdiltiazem for LTCCs is usually several orders of magnitude lower than that of D-cis-diltiazem. 25 Finally, we tested the effect of the DHP agonist BayK 8644 on Ca v 1.4␣1. At a concentration of 1 M this substance increased the current density of I Ba approximately sixfold. As in other LTCCs, BayK 8644 shifted the I-V relationship to approximately 8 to 10 mV more hyperpolarized potentials (Fig.  4B, Table 2 ).
DISCUSSION
In this study we report the cloning and the functional characterization of the Ca v 1.4␣1 calcium channel from mouse retina. Ca v 1.4␣1 requires the coexpression of auxiliary ␤ and ␣2␦ subunits to yield calcium currents in HEK293 cells. This finding indicates that Ca v 1.4␣1, like other members of the LTCC family forms a functional multisubunit complex in the plasma membrane. Currents obtained on coexpression with ␤2 had consistently bigger amplitudes than currents obtained with ␤3. One explanation for this finding is that although Ca v 1.4␣1 principally can assemble with different ␤ subunits, it preferentially binds to ␤2. The key role of the ␤2 subunit is also demonstrated by a recent study showing that elimination of this subunit in mouse retina produces a phenotype similar to FIGURE 2. Dependence of steady inactivation of Ca v 1.4␣1 on prepulse duration. Ba 2ϩ (30 mM) was used as the charge carrier. The following parameters were obtained: 5-second prepulse: V 0.5,inact ϭ 0.64 Ϯ 2.6 mV, k inact ϭ 17.5 Ϯ 0.8, n ϭ 9; 10-second prepulse: V 0.5,inact ϭ Ϫ20.1 Ϯ 1.6 mV, k inact ϭ 14.5 Ϯ 1.0 mV, n ϭ 8; 20-second prepulse: V 0.5,inact ϭ Ϫ21.4 Ϯ 2.1mV, k inact ϭ 10.1 mV Ϯ 1.0, n ϭ 7; 30-second prepulse: V 0.5,inact ϭ Ϫ25.7 Ϯ 1.9 mV, k inact ϭ 8.12 mV Ϯ 0.6, n ϭ 6. Ϫ24.3 Ϯ 1.5* 6.8 Ϯ 0.7* n ϭ 9 n ϭ 9 n ϭ 9 n ϭ 9 n ϭ 9 n ϭ 9 Ca v 1.4 ϩ ␤2a 30 Ba CSNB2 in humans. 26 In contrast, no retinal phenotype has been reported so far for ␤3-27 and ␤4-deficient mice. 28 Taken together, these findings strongly indicate that the ␤2 subunit is obligatorily required for the formation of native retinal LTCCs.
Ca v 1.4␣1 possesses unique biophysical and pharmacological properties that set this channel apart from the cardiac and smooth muscle Ca v 1. through the channel pore. Entering Ca 2ϩ interacts with calmodulin bound to the carboxyl terminus of the channel, thereby causing a decay of the current within milliseconds. 14, 24 The lack of Ca 2ϩ -dependent inactivation in Ca v 1.4␣1 indicates that either the binding of calmodulin itself or the conformational steps coupling Ca 2ϩ -binding to channel inactivation are impaired in this channel. The C-terminal sequences conferring Ca 2ϩ -dependent inactivation in Ca v 1.2␣ 24,29 -35 are highly conserved in Ca v 1.4␣. It is not known whether the few amino acid exchanges in these sequences explain the different inactivation properties of both channels. Alternatively, not yet identified channel domains may cause the lack of Ca 2ϩ -dependent inactivation in Ca v 1.4␣1. In the absence of the Ca 2ϩ -dependent mechanism the time course of currents through Ca v 1.4␣1 is determined primarily by voltage-dependent inactivation, causing the extremely slow current decay typical of Ca v 1.4␣1.
Ca v 1.4␣1 channels reveal a unique pharmacological profile. As for native retinal LTCCs, the apparent DHP antagonist sensitivity of Ca v 1.4␣1 is approximately 20-fold lower than for the cardiac and smooth muscle Ca v 1.2␣1 at Ϫ80 mV. Twelve of 13 amino acid residues required for high DHP sensitivity in Ca v 1.2␣1 are present in the primary sequence of Ca v 1.4␣1. 36 As the only difference, Ca v 1.4␣1 contains a phenylalanine at position 1414 instead of the tyrosine found in Ca v 1.2␣1. However, this exchange cannot account for the low affinity because Ca v 1.3␣1, a channel with a DHP sensitivity similar to that of Ca v 1.4␣1, 37 contains at the equivalent position a tyrosine, as does Ca v 1.2␣1. Although it cannot be excluded that there are other amino acids not yet identified that determine apparent affinities, it is probable that the differences reflect the profound voltage-dependence of the DHP block. In contrast to Ca v 1.2␣1, Ca v 1.4␣1 inactivates very slowly at negative holding potentials. Because DHPs bind preferentially to the inactivated state of LTCCs a decrease of apparent affinity is caused by this behavior. Indeed, shifting the holding potential from Ϫ80 to Ϫ50 mV, hence increasing the fraction of channels being in the inactivated state, strongly increased the DHP block of I Ba . The specific inactivation properties could also underlie the relatively low sensitivities of Ca v 1.4␣1 currents to verapamil and diltiazem. Unexpectedly, L-cis-diltiazem and D-cis-diltiazem blocked I Ba through Ca v 1.4␣1 with almost the same apparent IC 50 . In other LTCCs the affinity of D-cis-diltiazem is at least 20 times higher than that of L-cis-diltiazem. 25, 38, 39 In Ca v 1.2␣1 the binding site for diltiazem is overlapping with that for DHPs. 40 With the exception of the Y1414F exchange the identified amino acids are completely represented in Ca v 1.4␣1, indicating that other channel domains and/or a differential voltage dependence of the block by the D and L enantiomer of diltiazem determine the observed difference. Micromolar concentrations of L-cis-diltiazem are commonly used to block Ca 2ϩ flux through cyclic nucleotide-gated (CNG) channels in rod and cone photoreceptors. 41, 42 Because comparable concentrations also block calcium currents through Ca v 1.4␣1, extreme care is necessary to distinguish the effects of this blocker on CNG channels from those on retinal LTCCs.
In summary, currents through heterologously expressed Ca v 1.4␣1/␤2a/a2␦1 closely resemble the slowly inactivating Ca 2ϩ and Ba 2ϩ currents observed in native photoreceptors 4 -6 and bipolar cells. 8, 9 As the only difference, Ca 2ϩ currents from native photoreceptors and bipolar cells activate at 10 to 15 mV more negative potentials 4 -6,9,10 than currents obtained after heterologous expression of Ca v 1.4␣1. Several factors, such as the absence of auxiliary channel subunits, cytosolic modulators or posttranslational modifications in HEK293 cells, may explain the discrepancy between native and expressed channels. Nevertheless, its unique electrophysiological properties predestine Ca v 1.4␣1 to fulfill the specific tasks required for normal retinal function. In particular, the slow inactivation of Ca v 1.4␣1 is well suited to mediate tonic glutamate release from synaptic terminals of ribbon synapses in photoreceptors and bipolar cells. 9 The properties of mouse Ca v 1.4␣1 are consistent with those of the heterologously expressed human Ca v 1.4␣1. 43 For example, both channels lack Ca 2ϩ -dependent inactivation, assemble with ␤-subunits and reveal intermediate DHP sensitivity. The human Ca v 1.4␣1 activates at a slightly more negative voltage than the murine Ca v 1.4␣1. The small difference may be attributed to an intrinsic species difference between mouse and humans or, alternatively, may be due to the slightly different experimental setup used to study both currents. Taken together, our results indicate that mice deficient in this channel will be a useful in vivo model for studying CSNB2.
